Seeking Alpha

su

su
Send Message
View as an RSS Feed
View su's Comments BY TICKER:
Latest  |  Highest rated
  • AB Science : The French Exception ? [View instapost]
    Agree that the Celgene paclitaxel product is cytotoxic as is gemcitabine so combinations with the less toxic masitinib might be the likely outcome but will require further trials; have to wait til January to assess the measure of improvement in survival offered by celgene's study when they do a late breaking presentation at the American cancer conference.
    Nov 11 01:55 PM | Likes Like |Link to Comment
  • AB Science : The French Exception ? [View instapost]
    Have to agree that this is a much less invasive approach though a biopsy might still be required to confirm carcinoma rather than a mimic such as chronic pancreatitis or autoimmune IgG4 related pancreatitis; immunostains can be difficult and there may be grey areas due to limited tumour cells, equivocal staining, edge artefact.
    Don't know whether hent and sparc are membrane or cytoplasmic stains.
    Nov 9 08:18 AM | Likes Like |Link to Comment
  • AB Science : The French Exception ? [View instapost]
    Fourmi
    Pancreatic biopsies are difficult to obtain and dangerous to obtain as there are a lot of arterial vessels around the head of the pancreas, the commonest site for tumours, which can be punctured...
    Interpretation is also difficult as chronic pancreatitis can look quite similar to adenocarcinoma, particularly well differentiated carcinoma, and a lot of pancreatic cancers appear well differentiated which is quite surprising for such a lethal tumour.
    No direct experience of hent or Sparc immunostains but doubt whether they will tell you whether a given biopsy of pancreas is benign or malignant.. most immunostains at other sites don't.
    Nov 8 05:40 PM | Likes Like |Link to Comment
  • AB Science : The French Exception ? [View instapost]
    Fourmi
    Thank you for that comment;
    as a hstopathologist, I should be aware of how difficult pancreatic tumour biopsies can be to interpret though their number seems to have gone right down over the years perhaps as a result of centralisation of hepatobiliary surgery in this country, the UK...
    Nov 7 03:11 PM | Likes Like |Link to Comment
  • AB Science : The French Exception ? [View instapost]
    Just a little worried by the other drugs under development in phase 3 for pancreatic cancer including abraxane, and the Clavis drug not to mention the Threshold pharma drug in phase 2; the two phase 3 trials are about to read out in the fourth quarter
    Nov 6 09:32 AM | Likes Like |Link to Comment
  • AB Science : The French Exception ? [View instapost]
    Think you may be overegging the pudding;
    The primary end point was not met in this study although as you say sub group analysis was very impressive regarding the fantastic p value; don't believe the americans are very keen on subgroup analyses in cancer trials though.
    Further, we haven't been told of the side effects of the treatment and how many dropped out through side effects.
    That said, I was sufficiently encouraged to buy a few more last Thursday in view of the potential and the many trials underway not least the mastocytosis trial which should hopefully succeed.
    Nov 4 02:52 PM | Likes Like |Link to Comment
  • Clearing Up the Uncertainty Around MannKind’s Afrezza [View article]
    main concern is the carcinogenic risk; no one will know the risk of inhaling large doses of insulin several times a day for very many years; analogy is with mesothelioma and asbestos the incidence of which starts to rise 20 or more years after exposure.
    don't think non smokers will necessarily be protected since 10 per cent of lung cancers occur in non-smokers.
    So inhaled insulin might be best prescribed initially to older subjects or those unable to manage the injections... suggest people like me aged 55 or older.
    Dec 9 03:41 PM | 1 Like Like |Link to Comment
  • Will MannKind's Afrezza Succeed Where Pfizer's Exubera Failed? [View article]
    would have to net off the excess cancers, if any, caused by subcut insulin injections over a long period, particularly putative colorectal cancers with long-term use of glarcine; there is increased incidence of heptoma endometrial and pancreatic ca in patients with diabetes, particularly for hepatocellular ca, type 2 diabetes with the metabolic syndrome. In my case, I am in the mid-fifties with some early complications of type 1.5 so might be prepared to take the risk with inhaled insulin especially if there is a more physiological action profile as there was a high incidence of death due to heart disease in the family among males who did not have impaired glucose tolerance.
    Jul 28 12:52 PM | Likes Like |Link to Comment
  • Will MannKind's Afrezza Succeed Where Pfizer's Exubera Failed? [View article]
    as a patient with diabetes, this looks and sounds good but I am wary of the carcinogenic effect of insulin in the lungs from long-term use; only 10 years or more of studies would determine whether there was much of an increased risk
    Jul 28 09:49 AM | 1 Like Like |Link to Comment
COMMENTS STATS
9 Comments
2 Likes